Alnylam Pharma (ALNY) Misses Q3 EPS by 7c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.21), $0.07 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $13.7 million versus the consensus estimate of $9.14 million.

At September 30, 2016, Alnylam had cash, cash equivalents and marketable securities, and restricted investments of $1.19 billion, as compared to cash, cash equivalents and marketable securities of $1.28 billion at December 31, 2015.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Surf Air Mobility names Palantir veteran as president of SurfOS